Profile of bavituximab and its potential in the treatment of non-small-cell lung cancer

References

• American Cancer SocietyNon-Small Cell Cancer Survival Rates by Stage Available from: http://www.cancer.org/cancer/lungcancer-non-smallcell/detailedguide/non-small-cell-lung-cancer-survival-ratesAccessed May 22, 2013
   Google Scholar
• PetersSAdjeiAAGridelliCKerrKFelipEMetastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upAnn Oncol201223Suppl7vii56vii6422997455
   PubMed Web of Science ®Google Scholar
• SculierJPMoro-SibilotDFirst- and second-line therapy for advanced nonsmall cell lung cancerEur Respir J20093391593019336594
   PubMed Web of Science ®Google Scholar
• OxnardGRArcilaMEChmieleckiJLadanyiMMillerVAPaoWNew strategies in overcoming acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in lung cancerClin Cancer Res201117175530553721775534
   PubMed Web of Science ®Google Scholar
• ShepherdFADanceyJRamlauRProspective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapyJ Clin Oncol200018102095210310811675
   PubMed Web of Science ®Google Scholar
• HannaNShepherdFAFossellaFVRandomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapyJ Clin Oncol20042291589159715117980
   PubMed Web of Science ®Google Scholar
• ShepherdFARodriguesPJCiuleanuTErlotinib in previously treated non-small-cell lung cancerN Engl J Med200535312313216014882
   PubMed Web of Science ®Google Scholar
• HensingTASchellMJLeeJHSocinskiMAFactors associated with the likelihood of receiving second line therapy for advanced non-small cell lung cancerLung Cancer200547225325915639724
   PubMed Web of Science ®Google Scholar
• WillettCGBoucherYdi TomasoEDirect evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancerNat Med200410214514714745444
   PubMed Web of Science ®Google Scholar
• SoriaJCMauguenAReckMSystematic review and meta-analysis of randomised, phase II/III trials adding bevacizumab to platinum-based chemotherapy as first-line treatment in patients with advanced non-small-cell lung cancerAnn Oncol2013241203023180113
   PubMed Web of Science ®Google Scholar
• PatelJDSocinskiMAGaronEBPointBreak: a randomized phase III study of pemetrexed plus carboplatin and bevacizumab followed by maintenance pemetrexed and bevacizumab versus paclitaxel plus carboplatin and bevacizumab followed by maintenance bevacizumab in patients with stage IIIB or IV nonsquamous non–small-cell lung cancerJ Clin Oncol201331344349435724145346
   PubMed Web of Science ®Google Scholar
• MartinSJReutelingspergerCPMcGahonAJEarly redistribution of plasma membrane phosphatidylserine is a general feature of apoptosis regardless of the initiating stimulus: inhibition by overexpression of Bcl-2 and AblJ Exp Med19951825154515567595224
   PubMed Web of Science ®Google Scholar
• ZhaoJZhouQWiedmerTSimsPJLevel of expression of phospholipid scramblase regulates induced movement of phosphatidylserine to the cell surfaceJ Biol Chem199827312660366069506954
   PubMed Web of Science ®Google Scholar
• De RosePThorpePEGerberDEDevelopment of bavituximab, a vascular targeting agent with immune-modulating properties, for lung cancer treatmentImmunotherapy20113893394421843081
   PubMed Web of Science ®Google Scholar
• RanSThorpePEPhosphatidylserine is a marker of tumor vasculature and a potential target for cancer imaging and therapyInt J Radiat Oncol Biol Phys20025451479148412459374
   PubMed Web of Science ®Google Scholar
• LusterTAHeJHuangXPlasma protein beta-2-glycoprotein 1 mediates interaction between the anti-tumor monoclonal antibody 3G4 and anionic phospholipids on endothelial cellsJ Biol Chem200628140298632987116905548
   PubMed Web of Science ®Google Scholar
• RanSHeJHuangXSoaresMScothornDThorpePEAntitumor effects of a monoclonal antibody that binds anionic phospholipids on the surface of tumor blood vessels in miceClin Can Res200511415511562
   Web of Science ®Google Scholar
• ThorpePEVascular targeting agents as cancer therapeuticsClin Cancer Res200410241542714760060
   PubMed Web of Science ®Google Scholar
• FadokVABrattonDLKonowalAFreedPWWestcottJYHensonPMMacrophages that have ingested apoptotic cells in vitro inhibit proinflammatory cytokine production through autocrine/paracrine mechanisms involving TGF-beta, PGE2, and PAFJ Clin Invest199810148908989466984
   PubMed Web of Science ®Google Scholar
• ChenXDoffekKSuggSLShilyanskyJPhosphatidylserine regulates the maturation of human dendritic cellsJ Immunol200417352985299415322157
   PubMed Web of Science ®Google Scholar
• HeJYinYLusterTAAntiphosphatidylserine antibody combined with irradiation damages tumor blood vessels and induces tumor immunity in a rat model of glioblastomaClin Cancer Res200915226871688019887482
   PubMed Web of Science ®Google Scholar
• PregnolatoFChighizolaCBEncaboSAnti-phosphatidylserine/prothrombin antibodies: an additional diagnostic marker for APS?Immunol Res2013562–343243823572433
   PubMed Web of Science ®Google Scholar
• GerberDEStopeckAWongLPhase I safety and pharmacokinetic study of bavituximab, a chimeric phosphatidylserine-targeting monoclonal antibody, in patients with advaced solid tumorsClin Cancer Res2005172168886896
   Web of Science ®Google Scholar
• BeckmanRAvon RoemelingRScottAMMonoclonal antibody dose determination and biodistribution into solid tumorsTher Deliv20112333334422834004
   PubMedGoogle Scholar
• DigumartiRBapsyPPShanJSA phase Ib safety and pharmacokinetic study of bavituximab plus chemotherapy in patients with refractory advanced solid tumor malignanciesJ Clin Oncol (Meeting Abstracts)20082615 suppl:3038
   Web of Science ®Google Scholar
• ShtivelbandMSpigelDRGerberDERandomized, blinded, placebo-controlled phase II trial of docetaxel and bavituximab as second-line therapy in locally advanced or metastatic non-squamous non-small cell lung cancerJ Clin Oncol (Meeting Abstracts)201331suppl 8095
   Google Scholar
• DigumartiRSureshAVBharracharyyaGSDasappaLShanJPhase II study of bavituximab plus paclitaxel and carboplatin in untreated locally advanced or metastatic non-small cell lung cancer: interim resultsJ Clin Oncol (Meeting Abstracts)201028suppl 7589
   Google Scholar
• ReckMKaiserRMellemgaardADocetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trialLancet Oncol201415214315524411639
   PubMed Web of Science ®Google Scholar
• HerbstRSSunYEberhardtWEVandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC): a double-blind, randomised, phase 3 trialLancet Oncol201011761962620570559
   PubMed Web of Science ®Google Scholar
• ScagliottiGVKrzakowskiMSzczesnaASunitinib plus erlotinib versus placebo plus erlotinib in patients with previously treated advanced non-small-cell lung cancer: a phase III trialJ Clin Oncol201230172070207822564989
   PubMed Web of Science ®Google Scholar
• RamlauRGorbunovaVCiuleanuTEAflibercept and docetaxel versus docetaxel alone after platinum failure in patients with advanced or metastatic non-small-cell lung cancer: a randomized, controlled phase III trialJ Clin Oncol201230293640364722965962
   PubMed Web of Science ®Google Scholar